Cold Spring Biotech Corp. has introduced Quanterix's Simoa® p-Tau 217 blood test, which has received breakthrough designation from the FDA for its efficacy in aiding the diagnosis of Alzheimer’s disease (AD). This non-invasive, accessible tool addresses the urgent need for early AD diagnosis. CEO Masoud Toloue emphasized the importance of early detection for improving patient outcomes and establishing global AD testing infrastructure.

Alzheimer’s is a progressive neurodegenerative disease, and early diagnosis is crucial for slowing disease progression and enhancing patient quality of life. Traditional methods rely on invasive cerebrospinal fluid tests or expensive imaging, while the Simoa® p-Tau 217 blood test offers a convenient, low-cost alternative, enabling more patients to receive early diagnosis and treatment.

Furthermore, Cold Spring Biotech Corp. has already implemented this advanced testing technology in Taiwan, significantly enhancing early diagnosis capabilities, helping patients receive timely treatment, slowing disease progression, and improving quality of life. The laboratory uses Quanterix's immunomagnetic bead fluorescence technology to precisely detect trace brain neurodegenerative proteins that cross the blood-brain barrier, enabling regular monitoring of neurodegeneration risk.

Cold Spring Biotech Corp. will continue promoting the application of Quanterix's Simoa® p-Tau 217 blood test. In collaboration with NTU, TMU, CGMH, and other medical centers, they aim to accelerate clinical trials and new drug development, further utilizing this technology to study extracellular vesicles (EV). This initiative provides more innovative opportunities for Alzheimer’s medical research and pharmaceutical companies, aiding in the development of novel AD therapies and future targets for early cancer diagnosis.